Abeona Therapeutics reports $8.7M in Q1 2026 revenue, strong ZEVA skin adoption, and new oncology pipeline developments.

Key Takeaways

• Net product revenue for Q1 2026 reached $8.7 million, significantly up from $2.4 million in Q4 2025.
• The company treated five commercial patients with ZEVA skin, with six additional patients scheduled for biopsies this quarter.
• Cash reserves stood at $168.3 million, down from $191.4 million at the end of 2025, reflecting ongoing investments in commercialization.
• The percentage of commercially covered lives with ZEVA skin policies has reached 95% in the first year post-approval.
• Abeona anticipates IND filings for its new PSMA-directed T cell therapy in the second half of 2027.

Financial Performance

Abeona Therapeutics Inc. reported robust financial results for the first quarter of 2026, showcasing a strong start to the year. The company recorded $8.7 million in net product revenue, primarily driven by the early commercial traction of ZEVA skin, a treatment for recessive dystrophic epidermolysis bullosa (RDev). This marks a significant increase from $2.4 million in the previous quarter, indicating a $6.3 million quarter-over-quarter growth.

Operating expenses reflected the company's strategic focus, with R&D expenses at $9.6 million, slightly down from $9.9 million year-over-year, despite including a $7 million upfront payment for in-licensing its PSMA therapy. Selling, general, and administrative expenses rose to $19.5 million, largely due to the ramp-up of commercial infrastructure post-ZEVA skin approval. The net loss for the quarter was $17.1 million or $0.30 per share, compared to a net loss of $12 million or $0.24 per share in Q1 2025. The company ended the quarter with $168.3 million in cash and equivalents, positioning it well for future growth.

Strategic Initiatives

The launch of ZEVA skin has been a pivotal focus for Abeona. As of Q1 2026, the company has activated six qualified treatment centers (QTCs) and treated its fifth commercial patient. The demand for ZEVA skin remains strong, with over 100 patients identified across QTCs and community-based physicians. The company is actively working to expand its network of treatment centers, with plans to onboard up to seven QTCs by the end of the year.

Additionally, Abeona has made significant strides in its R&D pipeline. The company announced a new PSMA-directed T cell therapy for advanced prostate cancer, which is set to enter clinical trials in late 2027. This innovative therapy leverages advanced engineered T cell technology, aiming to address challenges faced by existing CAR T therapies. The in-licensing of this asset is viewed as a strategic move to diversify the company's offerings and tap into the oncology market.

Dr. Vish Seshadri, CEO, emphasized the importance of both ZEVA skin and the new PSMA therapy in addressing unmet medical needs. He noted the positive early feedback from treating physicians and the rising interest in ZEVA skin among the patient community, further enhancing its commercial outlook.

Future Outlook

Abeona's management expressed optimism regarding the future trajectory of ZEVA skin, highlighting a solid pipeline of patients awaiting treatment. The company anticipates continued commercial momentum, with a strong demand reflected in the near-term patient pool. As the company navigates the complexities of insurance approvals for high-cost gene therapies, it remains committed to optimizing patient access and driving awareness in the medical community.

Looking ahead, Abeona is focused on achieving monthly profitability as early as June 2026, contingent on patient treatment volumes and the successful navigation of the payer landscape. The management team is also vigilant about maintaining disciplined capital allocation to support both ZEVA skin commercialization and the development of its new oncology pipeline.

In summary, Abeona Therapeutics has demonstrated strong early commercial traction with ZEVA skin, backed by a robust financial position and a strategic focus on expanding its treatment and product pipeline. The company's commitment to patient care and innovative solutions positions it favorably for continued growth in the evolving landscape of gene therapies.

This analysis is based on public earnings call materials and is not investment advice.